tirzepatide fda ruling says the weight-loss drug shortage is over May 18, 2026: FDA warns

Widely used diabetes and obesity drugs show powerful heart-protective effects in high-risk patients, offering new momentum for their role in reducing cardiovascular deaths

While the retail cost for brands like Wegovy can seem high, working with insurance and our prior authorization support significantly reduces costs

And beyond the cost, there is the inconvenience of waiting for a replacement, the possibility of missing doses, and the disruption to a treatment plan that was finally working

If symptoms become severe or persistent, contact your healthcare providerdose reduction or temporary treatment interruption may be necessary

Food and Drug Administration, patients who used tirzepatide lost an average of 18 per cent of their body weight when it was taken at its highest dose in a drug trial

Women of childbearing potential taking an oral hormonal contraceptive should add a barrier contraceptive for 4 weeks after starting tirzepatide and after each dose escalation